2',4,5,6,7,7'-Hexafluorofluorescein | 195136-60-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2',4,5,6,7,7'-Hexafluorofluorescein
• 英文别名: 2',7',4,5,6,7-hexafluorofluorescein；2',4,5,6,7,7'-Hexafluoro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
• CAS: 195136-60-8
• 化学式: C₂₀H₆F₆O₅
• 分子量: 440.255
• InChiKey: KPWXVNOLJICAGE-UHFFFAOYSA-N

物化性质

• 沸点：
  611.3±55.0 °C(Predicted)
• 密度：
  1.87±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  31
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2',4,5,6,7,7'-Hexafluorofluorescein 以90%的产率得到2',4,5,6,7,7'-hexafluorofluorescein diacetate
  参考文献：
  名称：

  Fluorinated xanthene derivatives

  摘要：

  该发明的染料家族是直接在一个或多个芳香碳上被氟取代的荧光素和罗丹素。这些氟取代的荧光染料具有更高的光稳定性，在生理范围为6-8的pH变化下比非氟化染料具有较低的敏感性，当与物质结合时表现出较少的猝灭，并具有额外的优势。该发明的染料可用作可检测的示踪剂，并用于制备有机和无机物质的共轭物。

  公开号：

  US06162931A1
• 作为产物：
  描述：

  3,4,5,6-四氟苯酐 、 4-氟间苯二酚 以10.0 g (83%)的产率得到2',4,5,6,7,7'-Hexafluorofluorescein
  参考文献：
  名称：

  Fluorinated xanthene derivatives

  摘要：

  该发明的染料家族是直接在一个或多个芳香碳上被氟取代的荧光素和罗丹素。这些氟取代的荧光染料具有更高的光稳定性，在生理范围为6-8的pH变化下比非氟化染料具有较低的敏感性，当与物质结合时表现出较少的猝灭，并具有额外的优势。该发明的染料可用作可检测的示踪剂，并用于制备有机和无机物质的共轭物。

  公开号：

  US06162931A1

文献信息

• Improved Topical Medicaments and Methods for Photodynamic Treatment of Disease
  申请人：Provectus Pharmatech, Inc.

  公开号：EP2020242A2

  公开（公告）日：2009-02-04

  New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid or aerosol delivery vehicles.

  本文描述了用于治疗人类或动物组织的新型光动力局部应用药物及其某些医疗用途，其中此类药物的主要活性成分是卤代呫吨。卤代呫吨构成了一个强效光敏剂家族，当治疗部位受到可见光波长的照射时，卤代呫吨会被光激活。在优选的实施方案中，此类药物用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、各种其他内部或外部组织表面，如手术中暴露的组织表面的各种病症，以及治疗与微生物或寄生虫感染有关的各种病症。在另一个优选的实施方案中，这类药物以各种配方生产，包括液体、半固体或气溶胶给药载体。
• Composition and method for measuring thallium influx and efflux
  申请人：Life Technologies Corporation

  公开号：EP2562543A1

  公开（公告）日：2013-02-27

  The present invention relates to methods for detecting the activity of an ion channel in a cell. The methods comprise providing a loading buffer solution to a cell that has an ion channel. The loading buffer comprises at least one thallium indicator (e.g., an environmentally sensitive, luminescent dye) and a physiological concentration of chloride ions. The methods further comprise providing a stimulus buffer to the cell, wherein the stimulus buffer comprises thallium (e.g., thallium ions). Providing the stimulus buffer causes thallium influx into the cell through the ion channel. After providing the stimulus buffer, the luminescence (e.g., fluorescence) of the dye in the cell is detected. The luminescence of the dye can change in the presence or absence of thallium. The methods may be used to measure influx or efflux of thallium through an ion channel.

  本发明涉及检测细胞中离子通道活性的方法。这些方法包括向具有离子通道的细胞提供上载缓冲溶液。上载缓冲液包括至少一种铊指示剂（例如，环境敏感的发光染料）和生理浓度的氯离子。所述方法还包括向细胞提供刺激缓冲液，其中刺激缓冲液包括铊（如铊离子）。提供刺激缓冲液会导致铊通过离子通道流入细胞。提供刺激缓冲液后，检测细胞中染料的发光（如荧光）。铊存在或不存在时，染料的发光会发生变化。这些方法可用于测量铊通过离子通道的流入或流出。
• Intracorporeal medicaments for photodynamic treatment of disease
  申请人：Photogen, Inc.

  公开号：US20010022970A1

  公开（公告）日：2001-09-20

  New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

  本文描述了新的体腔内光动力药剂以及使用这种光动力药剂治疗人类或动物组织疾病的某些医疗用途和方法，其中这种药剂的主要活性成分是卤代呫吨或卤代呫吨衍生物。在优选的实施方案中，这类药物用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官、头颈部、内分泌和淋巴系统及相关器官、各种其他组织，如结缔组织和手术中暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织的各种疾病。在另一个优选的实施方案中，此类药物以各种剂型生产，包括液体、半固体、固体或气溶胶给药载体。
• Intracorporeal medicaments for high energy phototherapeutic treatment of disease
  申请人：Photogen, Inc.

  公开号：US20020001567A1

  公开（公告）日：2002-01-03

  New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

  本文描述了新的体腔内放射药剂以及使用这种高能光疗药剂治疗人体或动物组织的某些医疗用途和方法，其中这种药剂的主要活性成分是卤代呫吨或卤代呫吨衍生物。卤代呫吨构成了一个强效放射增敏剂家族，当电离辐射照射治疗部位时，这些增敏剂会发生光活化。在本发明的实施方案中，此类药剂可用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官、皮肤及相关器官、口腔及消化道及相关器官、泌尿道及生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官的各种疾病、循环系统及相关器官、头颈部、内分泌和淋巴系统及相关器官、各种其他组织，如结缔组织和手术中暴露的各种组织表面，以及出现微生物或寄生虫感染的各种组织。在另一个实施方案中，这类药剂以各种剂型生产，包括液体、半固体、固体或气溶胶给药载体。
• Medicaments for chemotherapeutic treatment of disease
  申请人：Photogen, Inc.

  公开号：US20020161035A1

  公开（公告）日：2002-10-31

  New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

  本文描述了新的化疗药物以及使用此类化疗药物治疗人类或动物组织疾病的某些医疗用途和方法，其中此类药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。卤化氧杂蒽最好是玫瑰红或玫瑰红的功能衍生物。卤代呫吨构成了一个有用的化疗药物家族，可以在某些组织中选择性地、持久地蓄积。在优选的实施方案中，这类药剂用于治疗影响皮肤和相关器官、口腔和消化道及相关器官、泌尿道和生殖道及相关器官、呼吸道及相关器官、循环系统及相关器官、头颈部、内分泌和淋巴系统及相关器官、各种其他组织，如结缔组织和手术中暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织的各种病症。在另一个优选的实施方案中，这类药剂以各种配方生产，可用于体腔内或局部给药，包括液体、半固体、固体或气溶胶给药载体。